- Home
- XERS vs SCSC Comparison
XERS vs SCSC Comparison
Compare XERS & SCSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | SCSC |
|---|---|---|
| Founded | 2005 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | XERS | SCSC |
|---|---|---|
| Price | $8.59 | $51.53 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | $10.83 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 2.3M | 207.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | 0.01 | ★ 2.42 |
| Revenue | $49,590,000.00 | ★ $3,846,260,000.00 |
| Revenue This Year | $34.37 | $2.60 |
| Revenue Next Year | $22.86 | $4.01 |
| P/E Ratio | $883.00 | ★ $21.29 |
| Revenue Growth | ★ 142.67 | 7.79 |
| 52 Week Low | $4.87 | $33.76 |
| 52 Week High | $10.08 | $53.14 |
Technical Indicators
Market Signals| Indicator | XERS | SCSC |
|---|---|---|
| Relative Strength Index (RSI) | 78.63 | 65.09 |
| Support Level | $6.86 | $38.55 |
| Resistance Level | $10.08 | N/A |
| Average True Range (ATR) | 0.32 | 1.23 |
| MACD | 0.13 | -0.11 |
| Stochastic Oscillator | 80.98 | 68.62 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.